Inhibition with spontaneous reactivation and the "ongoing inhibition" effect of esterases by biotinylated organophosphorus compounds: S9B as a model.
The biotinylated organophosphorus compound 1-(saligenin cyclic phospho)-9-biotinyldiaminononane (S9B) has been used for the detection, labeling and isolation of the membrane-bound neuropathy target esterase (NTE) as it was considered a specific inhibitor of NTE. After incubation with the soluble fraction of chicken peripheral nerve, most of the soluble esterase activity was highly sensitive to S9B, indicating NTE-like esterases. A kinetic model equation was used to assume a multi-enzymatic system with three different simultaneously occurring molecular phenomena; (1) inhibition; (2) simultaneous spontaneous reactivation; and (3) ongoing inhibition (inhibition during the substrate reaction); to fit the data to analyze kinetic behavior. A high "ongoing inhibition" effect was observed in an enzymatic component. A three-dimensional fit of the model was applied. The best fitting model is compatible with three sensitive enzymatic entities (33, 52 and 15%), and only one spontaneously reactivate. The second-order rate constants of inhibition (k(i)=116 x 10(6), 4.6 x 10(6) and 0.28 x 10(6)M(-1)min(-1), respectively) and the spontaneous reactivation constant for the first sensitive component (k(r)=0.0054 min(-1)) were simultaneously estimated. These parameters are similar to those deduced in spontaneous reactivation experiments of the preinhibited samples with S9B. The estimated proportions of enzymatic components are similar to those previously observed in inhibition experiments with mipafox, demonstrating that this kinetic approach offers consistent results.
Estévez
Jorge
J
Unidad de Toxicología, Instituto de Bioingeniería, Universidad Miguel Hernández, Elche (Alicante), Spain. jorge.estevez@umh.es
Barril
José
J
Vilanova
Eugenio
E
D000818:Animals; D001710:Biotin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology; D019921:Biotinylation; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology*; D004950:Esterases / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism*; D007700:Kinetics; D009943:Organophosphorus Compounds / Q000737:chemistry* / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology*; D010525:Peripheral Nerves / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D012995:Solubility; D014462:Ultrafiltration
D004791:Enzyme Inhibitors; D009943:Organophosphorus Compounds; C088489:1-(saligenin cyclic phospho)-9-biotinyldiaminononane; D001710:Biotin; D004950:Esterases